SOTAHEXAL

This brand name is authorized in Austria, Brazil, Germany, Estonia, Poland, Singapore, South Africa

Active ingredients

The drug SOTAHEXAL contains one active pharmaceutical ingredient (API):

1 Sotalol UNII HEC37C70XX - SOTALOL HYDROCHLORIDE

D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Read about Sotalol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C07AA07	Sotalol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective
Discover more medicines within C07AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 511510301115416, 511513100057903, 511514090059103
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 07254206, 07254212, 07254229, 07561026, 07561049, 07704968, 07704980
Country: EE	Ravimiamet	Identifier(s): 1034480, 1071863, 1678169, 1678170
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100062357, 100062363, 100118371
Country: SG	Health Sciences Authority	Identifier(s): 13311P
Country: ZA	Health Products Regulatory Authority	Identifier(s): 29/5.2/0749, 29/5.2/0750